Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE ACETATE 1 AND PRAMOXINE HYDROCHLORIDE 1 versus SOLU CORTEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE ACETATE 1 AND PRAMOXINE HYDROCHLORIDE 1 versus SOLU CORTEF.
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1% vs SOLU-CORTEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone acetate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, vasodilation, and immune cell activity. Pramoxine hydrochloride is a local anesthetic that reversibly blocks sodium ion channels in nerve cell membranes, inhibiting nerve impulse conduction and providing topical anesthesia.
Solu-Cortef (hydrocortisone sodium succinate) is a corticosteroid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators, including prostaglandins and leukotrienes. It also inhibits immune cell migration and activation.
Apply a thin film to affected area three to four times daily. Topical only.
100-1000 mg intravenous (IV) or intramuscular (IM), then 100-500 mg IV or IM every 2-6 hours as needed.
None Documented
None Documented
Hydrocortisone acetate: 1.5–2 hours (plasma), clinically adrenocortical suppression lasts 24–48 hours; pramoxine: not applicable due to minimal absorption.
Terminal elimination half-life: 1.5-2 hours (hydrocortisone); clinical duration of action is longer due to genomic effects (6-8 hours).
Hydrocortisone acetate: primarily renal (about 90% as metabolites, less than 1% unchanged); pramoxine HCl: negligible systemic absorption, eliminated primarily via fecal excretion.
Renal: ~80% as metabolites (mainly 17-hydroxycorticosteroids) and <5% unchanged. Biliary/fecal: minimal (<5%).
Category D/X
Category C
Corticosteroid
Corticosteroid